接种带状疱疹疫苗与痴呆症风险降低相关联

Brown大学的研究发现，接种Shingrix带状疱疹疫苗与老年人痴呆症诊断风险降低存在关联。1该研究分析了超过50万名66岁及以上老年人的数据，其中8,843人接种了疫苗。1研究显示，接种者中18.8%在四年内患上痴呆症，而未接种者的发病率为24.6%，相当于痴呆症诊断风险降低24%。1

根据研究数据，每17人接种可能预防约1例痴呆症病例。1这项研究对象为2017年至2022年间入住5,500多家护理机构的患者，相关发现已发表在《内科学年鉴》2026年第179卷第7期上。1Shingrix是目前市场上唯一可用的带状疱疹疫苗，于2017年推出。1

该研究资金来自Shingrix制造商葛兰素史克公司。1

Researchers at Brown University have found that older adults who received the Shingrix shingles vaccine experienced a 24% reduction in dementia diagnoses over a four-year period.1 The study analyzed data from more than 500,000 people aged 66 and older, comparing dementia diagnosis rates between vaccinated and unvaccinated groups.1 Among vaccine recipients, 18.8% developed dementia, compared to 24.6% of those who did not receive the vaccine, suggesting that vaccinating approximately 17 people could prevent about one case of dementia.1

The research examined patients admitted to more than 5,500 nursing facilities between 2017 and 2022, involving 509,926 total participants of whom 8,843 received the vaccine.1 Shingrix, which became available in 2017, is currently the only shingles vaccine available on the market.1 The findings were published in the Annals of Internal Medicine in 2026.1 The research was funded by GlaxoSmithKline, the manufacturer of Shingrix.1